Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1305-1314

  Uddin, Shahab ^a   Bu, Rong ^a   Ahmed, Maqbool ^a   Hussain, Azhar R ^a   Ajarim, Dahish ^a   Al Dayel, Fouad ^a   Bavi, Prashant ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

DLBCL; leptin receptor; PI3K AKT pathway

Indexed keywords

LEPTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LEPTIN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LEPTIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 77954096916     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003802365     Document Type: Article

References (35)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3916.
2. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large Bcell lymphomas. Blood 2005;105:2916-2923.
3. Hartge P,Wang SS.Overviewof the etiology and epidemiology of lymphoma. In:MauchPM,Armitage JO,CoiffierB,Dalla-Favera R, Harris NL, editors. Non-Hodgkin's lymphomas. New York: Lippincott, Williams &Wilkins; 2004. pp 711-727.
4. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett 2003;546:45-50.
5. Hegyi K, Fulop K, Kovacs K, Toth S, Falus A. Leptininduced signal transduction pathways. Cell Biol Int 2004;28:159-169.
6. Uotani S, Bjørbaek C, Tornøe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999;48:279-286.
7. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001;2:278-289.
8. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 30-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186.
9. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004;10:4325-4331.
10. Garofalo C, Koda M, Cascio S, et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 2006;12:1447-1453.
11. Hardwick JCH, van Den Brink GR, Offerhaus GJ, van Deventer SJH, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001;121:79-90.
12. Schneider R, Bornstein SR, Chrousos GP, Boxberger S, Ehninger G, Breidert M. Leptin mediates a proliferative response in human gastric mucosa cells with functional receptor. Horm Metab Res 2001;33:1-6.
13. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998;281:1683-1686.
14. Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999;93:1668-1676.
15. Nakao T, Hino M, Yamane T, Nishizawa Y, Morii H, Tatsumi N. Expression of the leptin receptor in human leukaemic blast cells. Br J Haematol 1998;102:740-745.
16. Wex H, Ponelis E, Wex T, Dressendö rfer R, Mittler U, Vorwerk P. Plasma leptin and leptin receptor expression in childhood acute lymphoblastic leukemia. Int J Hematol 2002;76:446-452.
17. Reseland JE, Reppe S, Olstad OK, et al. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. J Haematol 2009;83:460-470.
18. Mouzaki A, Panagoulias I, Dervilli Z, et al. Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. Cytokine 2009;48:203-211.
19. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006;28:241-244.
20. Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S. Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol 2007;60:902-906.
21. Uddin S, Bavi PP, Hussain AR, et al. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009;30:1832-1840.
22. Hong SJ, Kwon KW, Kim SG, et al. Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine 2006;33:66-71.
23. Uddin S, Bu R, Ahmed M, et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009;8:74.
24. Uddin S, Bavi P, Siraj A, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer 2010;17:191-202.
25. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004;10:4325-4331.
26. Hussain AR, Al-Jomah NA, Siraj AK, et al. Sanguinarinedependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007;67:3888-3897.
27. Hussain AR, Ahmed M, Al-Jomah NA, et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008;7:3318-3329.
28. Uddin S, Hussain AR, Ahmed M, et al. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol 2009;104:1790-1801.
29. Uddin S, AhmedM, Bavi P, et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008;68:3379-3388.
30. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006;207:12-22.
31. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007;94:346-354.
32. Ogunwobi OO, Beales IL. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNKmitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 2007;22:401-409.
33. Saxena NK, Sharma D, Ding X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007;67:2497-2507.
34. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001;21:952-965.
35. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241.